مجله علوم پزشکی پارس

لیپوپروتئین با چگالی پایین اکسید شده در سکته قلبی حاد: یک مطالعه مورد-شاهدی

نویسندگان

1 استادیار، گروه قلب و عروق،دانشگاه علوم پزشکی شیراز،شیراز،ایران

2 استاد، مرکز تحقیقات بیماری های غیرواگیر، دانشگاه علوم پزشکی، جهرم، ایران

3 متخصص داخلی،دانشگاه علوم پزشکی شیراز،شیراز،ایران

4 بخش مراقبت قلب، بیمارستان پیمانیه،دانشگاه علوم پزشکی جهرم، جهرم،ایران

5 دانشیار، مرکز تحقیقات مولفه های اجتماعی سلامت،دانشگاه علوم پزشکی جهرم، جهرم،ایران

چکیده

مقدمه: متابولیسم بسیاری از چربی ها از جمله اسیدهای چرب آزاد و لیپوپروتئین با چگالی پایین اکسید شده ( Oxidized Low Density Lipoprotein, ox-LDL) نقش مهمی در ایجاد آترواسکلروزیس دارد. هدف از انجام مطالعه حاضر تعیین ارتباط این لیپوپروتئین با سکته قلبی حاد بود.
روش کار: مطالعه مورد- شاهدی روی 43 بیمار مبتلا به سکته قلبی حاد و 43 فرد فاقد نشانه ها و سابقه بیماری قلبی-عروقی یا مغزی-عروقی همسان شده با بیماران از نظر سن و جنسیت انجام شد. از کیت الیزا ساخت شرکت مرکودی، سوئد برای سنجش لیپوپروتئین با چگالی پایین اکسید شده استفاده شد. داده ها به کمک نرم افزار SPSS، نسخه 16 ثبت و سپس تجزیه و تحلیل شدند. سطح معناداری آماری کمتر از 0.05 در نظر گرفته شد.
یافته ها: دو گروه مورد بررسی از نظر سن، جنسیت، استعمال سیگار، سابقه خانوادگی ایسکمی قلبی، هیپرتری گلیسیریدمی، هیپرکلسترولمی، پرفشاری خون، دیابت قندی نوع 2 و وجود بیماری، اختلاف معناداری نداشتند. میانگین غلظت سرمی لیپوپروتئین با چگالی پایین اکسید شده در گروه بیماران و شاهد تفاوت معناداری داشت و میزان آن در گروه مورد (µg/ml 2.14 ± 1.67) بیشتر از گروه شاهد (µg/ml 1.03 ± 1.18) بود ( P=0.001 ). با استفاده از رگرسیون لجستیک چند متغیره و ورود متغیرهای مورد مطالعه در مدل، عامل  LDL اکسید شده به طور مستقلی با خطر بروز سکته قلبی حاد (OR= 1.74, CI95%: 1.2-20.52, p= 0.003) همراه بود.
نتیجه گیری: افزایش  LDL اکسید شده با سکته قلبی حاد ارتباط دارد و ممکن است در تشخیص سکته قلبی کمک کننده باشد.
 

کلیدواژه‌ها

عنوان مقاله [English]

Oxidised LDL in Acute Myocardial Infarction: A Case-Control Study

نویسندگان [English]

  • Payman Izadpanah 1
  • Mohammad Shojaei 2
  • Zahra Shiebani 3
  • Amin Mosalanejad 4
  • Karamatollah Rahmanian 5

1 Assisstant Professor, Deputy of Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran

2 Professor, Research Center for Non Communicable Disease, Jahrom University of Medical Sciences, Jahrom, Iran

3 Internist, Shiraz University of Medical Sciences, Shiraz, Iran

4 Cardiac Care Unit, Peimanieh Hospital, Jahrom University of Medical Sciences, Jahrom, Iran

5 Associate Professor, Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran

چکیده [English]

Introduction: The metabolism of many fats, including free fatty acids and oxidized low density lipoprotein (ox-LDL)
play an important role in the development of atherosclerosis. The aim of this study was to determine the association between circulating ox-LDL and acute myocardial infarction.
Materials and Methods: The case control study conducted on 43 patients with acute myocardial infarction and 43 volunteers who had no signs, symptoms or history of cardiovascular or cerebrovascular disease and matched to
patients for age and sex (control). We used ELISA kit (company of Mercodia, Sweden) to measure circulating ox-LDL. The data recorded and then analyzed by SPSS software version 16. Statistical significance was considered as p-value less than 0.05.
Results: Two study groups significantly were no differences as age, sex, smoking, family history of ischemic heart disease, hypertriglyceridemia, hypercholesterolemia, hypertension, diabetes mellitus type 2, and disease existence. There was a significant difference between the mean concentration of ox-LDL in AMI and control group as it was higher in the patients (2.14 ± 1.67 μg/ml) than the controls (1.03 ±1.18 μg/ml, p= 0.001). Using logistic regression analysis and entering variables of study in the model, ox-LDL factor was independently associated with the risk of myocardial infarction (OR= 1.74, CI95%: 1.2-20.52, P= 0.003).
Conclusions: Elevated ox-LDL is associated with the acute myocardial infarction and may also be helpful in the early
detection of myocardial infarction.

کلیدواژه‌ها [English]

  • Oxidised LDL
  • Myocardial Infarction
  • Family History
  • Smoking
1. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2016;68(10):1082-115. 2. Mokdad AH, Tehrani-Banihashemi A, Moradi-Lakeh M, El.Bcheraoui C, Charara R, Khalil I, et al. Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018;63 (Suppl 1):S137–S49. 3. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014;129:1493–501. 4. Gómez M, Valle V, Arós F, Sanz G, Sala J, Fiol M, et al. Oxidized LDL, Lipoprotein (a), and Other Emergent Risk Factors in Acute Myocardial Infarction (FORTIAM Study). Rev Esp Cardiol. 2009;62(4):373-82. 5. Ueba T, Nomura S, Nishikawa T, Kajiwara M, Yamashita K. Circulating oxidized LDL, measured with FOH1a/DLH3 antibody, is associated with metabolic syndrome and the coronary heart disease risk score in healthy Japanese. Atherosclerosis. 2009;203:243–8. 6. Sarkar PD, Rautaray SS. Oxidized LDL and Paraoxanase Status in Ischemic Stroke Patients. Indian J Physiol Pharmacol. 2008;52 (4):403–7. 7. Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry. 2003;74:312–6. 8. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci. 2016;13(1):25–38. 9. Asadpour.Piranfar M, Pordal AH, Rajabiani A, Abdelahi M, Hedayati M. Serum Level of Ox-LDL and Activity of Superoxid Disudium in Hypertensive Patients. Researcher Bulletin of Medical Sciences (Pejouhande) 2008 13 (61)(1):53-7. 10. Neiafar M, Esfahanian F, Esteghamati A, Heshmat R, Hedayati M, Karami M, et al. Comparison of Oxidized LDL and Anti Oxidized LDL Antibody Levels Between Type 2 Diabetic Patients and Normal People. Iranian Journal of Diabetes and Lipid Disorders. 2005;4(4):21-5. 11. Hackam D, Anard S. Emerging risk factors for atherosclerotic vascular disease. JAMA. 2003;290:932-40. 12. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): Shortterm and long-term immunologic responses to oxidized lowdensity lipoprotein. Circulation. 2004;109:3164-70. 13. Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Karetnikova V, Shilov A, et al. Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids in Health and Disease. 2014;13:111. 14. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15:2073–84. 15. Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 1994;108:S21–S9. 16. Steinberg D. Clinical trails of antioxidants in atherosclerosis: are we doing the right thing? . Lancet. 1995;346:36–8. 17. Li D, Mehta JL. Oxidized LDL, a critical factor in atherogenesis. Cardiovascular Research. 2005;68(3):353-4. 18. Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. Atherosclerosis. 2015;239(2):439-43. 19. Weinbrenner T, Cladellas M, Isabel CM, Fitó M, Tomás M, Sentí M, et al. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis. 2003;168(1):99–106. 20. Shimada K, Mokuno H, E M, Miyazaki T, Sumiyoshi K, Miyauchi K, et al. Circulating oxidized lowdensity lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004;174(2):343–7. 21. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–60. 22. Cheriyan S, Nandakumaran DG, Roy DD, Mahendra J, Krishnan V. Oxidised LDL Cholesterol (Ox-LDL-C) and Ox-LDL-C/HDL Cholesterol (HDL-C) Ratio in Acute Coronary Syndrome Patients versus Chronic Coronary Artery Disease Patients on Statin Treatment. Journal of Clinical and Diagnostic Research. 2019;13(12):BC14-BC7. 23. Taghiyan Jamaleddin Kolaie SS, Kalantarhormozi M, Darabi H, Assadi M, Ostovar A, Pourbehi M, et al. The association between MDA-oxidised LDL, antibodies against oxidised LDL and ischemic heart disease in postmenopausal women: a population-based study. Iranian South Medical Journal. 2016;19(2):306-19. 24. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J Am Coll Cardiol. 2006;48:973–9. 25. Ghosh J, Mishra TK, Rao YN, Aggarwal SK. Oxidised LDL, HDL Cholesterol, LDL Cholesterol Levels in Patients of Coronary Artery Disease. Indian Journal of Clinical Biochemistry. 2006;21 (1):181-4. 26. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, et al. The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort. DIABETES 2004;53:1068-73. 27. Holvoet P, Vanhaecke J, Janssens S, Van.de.Werf F, Collen D. Oxidized LDL and Malondialdehyde-Modified LDL in Patients With AcuteCoronary Syndromes and Stable Coronary Artery Disease. Circulation. 1998;98:1487-94. 28. Zhang YC, Tang Y, Chen Y, Huang XH, Zhang M, Chen J, et al. Oxidized Low-Density Lipoprotein and C-Reactive Protein Have Combined Utility for Better Predicting Prognosis After Acute Coronary Syndrome. 2014;68(2):379-85. 29. Watt J, Kennedy S, Ahmed N, Hayhurst J, McClure JD, Berry C, et al. The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. Open Heart. 2016;3(1):e000342. 30. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J BiolChem. 1997;272(34):20963–6. 31. Flavahan NA. Atherosclerosis or liprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992;85:1927-38. 32. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112:651-7.
مجله علوم پزشکی پارس
دوره 18، شماره 1 - شماره پیاپی 51
فروردین 1399
صفحه 8-14